NCT04932954

Brief Summary

This is a hospital-based retrospective cohort study and the Immunohematologic characteristics of COVID-19 patients will be investigated systematically.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
2,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2020

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2020

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

June 17, 2021

Completed
4 days until next milestone

First Posted

Study publicly available on registry

June 21, 2021

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2022

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2023

Completed
Last Updated

June 21, 2021

Status Verified

June 1, 2021

Enrollment Period

2 years

First QC Date

June 17, 2021

Last Update Submit

June 17, 2021

Conditions

Covid19

Keywords

ImmunohematologyBlood groupCOVID-19

Outcome Measures

Primary Outcomes (2)

  • ABO and Rh distribution

    ABO and Rh phenotype distribution refers to the phenotype frequency of the ABO and Rh subtypes in severe and non-severe COVID-19 patients

    1 year

  • ABO antibody titers

    ABO antibody titers refers to both anti-A and anti-B antibodies in severe and non-severe COVID-19 patients

    1 year

Secondary Outcomes (5)

  • Transfusion incidence

    1 year

  • Patients with coagulopathy

    1 year

  • Leukocyte and neutrophil counts

    1 year

  • outcomes of SARS-CoV-2 infection

    1 year

  • Polymorphism of ABO blood group

    1 year

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The patients were diagnosed with COVID-19 following the WHO interim guidelines and admitted for treatment in Tongji hospital. The admission dates were January 01 2020 to April 01, 2021. Male or female patients \<18 years of age were excluded.

You may qualify if:

  • The patients who were diagnosed with COVID-19 following the WHO interim guidelines (https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novelcoronavirus-(ncov)-infection-is-suspected. 2020.)

You may not qualify if:

  • Male or female patients \<18 years of age

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tongji Hospital

Wuhan, Hubei, 430000, China

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
professor

Study Record Dates

First Submitted

June 17, 2021

First Posted

June 21, 2021

Study Start

January 1, 2020

Primary Completion

January 1, 2022

Study Completion

January 1, 2023

Last Updated

June 21, 2021

Record last verified: 2021-06

Locations

CN(1)